Treatment options for metastatic renal cell carcinoma: a review.
about
Prolonged survival after sequential multimodal treatment in metastatic renal cell carcinoma: two case reports and a review of the literature.The incidence of renal cancer in Polish National Cancer Registry: is there any epidemiological data we can rely on?Prognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy.High NUCB2 expression level represents an independent negative prognostic factor in Chinese cohorts of non-metastatic clear cell renal cell carcinoma patientsNovel immunotherapy in metastatic renal cell carcinoma.Lack of ephrin receptor A1 is a favorable independent prognostic factor in clear cell renal cell carcinoma.Clinical outcome of advanced and metastatic renal cell carcinoma treated with targeted therapy: is there a difference between young and old patients?Forkhead box J1 expression is upregulated and correlated with prognosis in patients with clear cell renal cell carcinoma.Changes in clinicopathological characteristics of renal cell carcinoma in the past 25 years: a single-center experience.Treatment of patients with metastatic renal cell carcinoma undergoing hemodialysis: case report of two patients and short literature reviewSerum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinomaIncreased expression of system large amino acid transporter (LAT)-1 mRNA is associated with invasive potential and unfavorable prognosis of human clear cell renal cell carcinoma.Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis surveyBone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?Expression of IL-4 and IL-13 predicts recurrence and survival in localized clear-cell renal cell carcinoma.Synergistic immunotherapeutic effects of Lycium barbarum polysaccharide and interferon-α2b on the murine Renca renal cell carcinoma cell line in vitro and in vivo.High Level of Anaphylatoxin C5a Predicts Poor Clinical Outcome in Patients with Clear Cell Renal Cell Carcinoma.Prognostic and Clinicopathological Significance of Survivin Expression in Renal Cell Carcinoma: A Systematic Review and Meta-AnalysisRibosomal s6 protein kinase 4: a prognostic factor for renal cell carcinomaThe epidemiology and risk factors for renal cancer.Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma.Meta-analysis of the efficacy of the pretreatment neutrophil-to-lymphocyte ratio as a predictor of prognosis in renal carcinoma patients receiving tyrosine kinase inhibitors.Enrichment of C5a-C5aR axis predicts poor postoperative prognosis of patients with clear cell renal cell carcinoma.Renal cell carcinoma: how to hit the targets?Clinicalpathological and prognostic significance of survivin expression in renal cell carcinoma: a meta-analysis.Predicting Molecular Models: Where Are We Going?Axitinib induces DNA damage response leading to senescence, mitotic catastrophe, and increased NK cell recognition in human renal carcinoma cellsMetastatic renal cell carcinoma to the testis: A case report and review of the literature.Prognostic and clinicopathological role of high Ki-67 expression in patients with renal cell carcinoma: a systematic review and meta-analysis.Progression-free survival of first-line treatment with molecular-targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma.Tumor-suppressing effects of microRNA-429 in human renal cell carcinoma via the downregulation of Sp1.Notch 1 is a valuable therapeutic target against cell survival and proliferation in clear cell renal cell carcinoma.Unusual presentation of renal cell carcinoma: gluteal metastasis.Elevated expression of KIF18A enhances cell proliferation and predicts poor survival in human clear cell renal carcinoma.Indirect comparisons of efficacy and safety between seven newer targeted agents for metastatic renal cell carcinoma: A network meta-analysis of randomised clinical trials.Systematic Analysis of Transcriptomic Profile of Renal Cell Carcinoma under Long-Term Hypoxia Using Next-Generation Sequencing and Bioinformatics.Management of metastatic renal cell carcinoma - mini review.Down-regulation of transient receptor potential melastatin member 7 prevents migration and invasion of renal cell carcinoma cells via inactivation of the Src and Akt pathway.High expression of correlates with aggressive features and poor survival in clear cell renal cell carcinoma
P2860
Q30565687-9DAAD5BD-C631-43D4-B149-2BC584105C5CQ30854594-0CF3605D-FB98-4744-A494-574B5DB751F8Q33431578-10AD3167-5BD3-4903-8C6F-1855F7C31E3BQ33798805-F15B9D56-27A4-4083-B636-72641AFE3416Q33863074-CF7A234B-F1F8-46C4-BF9E-8EAF114FD06EQ33904883-4277AB37-A9E5-4A72-A25D-9C02BE16E5F9Q34471312-FF8B3B88-8C09-40A9-BE15-651F352C1191Q34503610-4A55010B-5A6F-48FA-8DFC-6C705A612A45Q34609828-A34A2560-A741-49FD-BAB3-31FA7A57F48EQ34668974-7398E088-ED71-4906-A2F3-CE53EBCA8BFEQ34995745-C422A267-FE0D-4477-BDB1-4E25876C483FQ35028079-C91C8A31-EE0E-4287-A1FA-CCE08C21505CQ35080143-4A4A7132-FFAD-442E-BF93-4673290A3A03Q35083485-138827FB-9CF0-4013-A4A5-5F7473B62F31Q35405080-7172BB1F-734C-4FD5-AF20-6EFC065A0C79Q36224768-F21FDFF4-7CE4-4E9C-995C-553897FD3CD2Q37067601-BBF2CF53-EA06-4219-8677-D127686929FFQ37093298-3F978CCC-9D8E-4A24-B8C3-AA23E5A2B218Q37185851-03AFF44A-B530-42EE-9EF7-AA18C326EE3FQ37198045-2DB8C11D-9491-4737-9B86-0D92E5860186Q37362945-D7EB5E2D-07D7-4672-87C5-783874997C3BQ37536769-7A236876-F117-473B-8484-D64087875006Q37697095-CAD090D0-7E9C-45BE-871C-0A02D1553C0BQ37711561-BD8B5E93-0A8F-47A5-992A-C89C09986812Q37746154-53120776-C828-484D-A1FF-38DC47C85EA8Q38255286-6F3CBFC2-5DE6-48EB-9281-608DE061A4D8Q38262918-A23E02C8-6530-4993-BE42-6B8E7452A16CQ38305091-18E8148C-1580-4C3E-AA34-B3385783EFEAQ39175825-29D1BD75-4F2D-4DD2-B1F3-94B9795522A3Q41145898-6E481741-7D69-4002-B2A1-559008A24DB1Q41196528-A0E9AF0C-6F68-4EC0-BC60-9326D590779EQ41621168-2A4AD3BD-1A96-4728-A3FD-1470CC45435FQ42168101-750EA480-E215-4FDA-B959-22E9FAE05BD0Q42722494-5597A8B5-1F5C-499C-9684-FA9A1B4ABED4Q42743224-E5D99F55-31B2-4F68-BA6B-B5D71B7523FFQ48160019-88D652A8-C5CB-43A5-A924-745F2934DA15Q53848926-D15A6814-6E55-48AA-9ADB-AABC767C21CAQ55447540-87B398AD-B566-4A9E-8643-02ABA801D9C3Q57116316-07B2520C-7D65-42A4-BBA1-A289B2494326
P2860
Treatment options for metastatic renal cell carcinoma: a review.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treatment options for metastatic renal cell carcinoma: a review.
@en
Treatment options for metastatic renal cell carcinoma: a review.
@nl
type
label
Treatment options for metastatic renal cell carcinoma: a review.
@en
Treatment options for metastatic renal cell carcinoma: a review.
@nl
prefLabel
Treatment options for metastatic renal cell carcinoma: a review.
@en
Treatment options for metastatic renal cell carcinoma: a review.
@nl
P1476
Treatment options for metastatic renal cell carcinoma: a review
@en
P2093
Teresa C Gentile
Uzma Athar
P304
P577
2008-04-01T00:00:00Z